Pfizer's development of Comirnati (a vaccine against COVID-19) has certainly pulled all the attention of investors and analysts, switching most of the conversation on the company's topic last year. It is exactly what is most talked about and argued about on Wall Street. The real story, however, is CEO Albert Burla's vision for a more streamlined, innovation-oriented company. He outlined his strategy when he took office in 2019, and Komirnati is just an early sign that the transformation is working.
Our Analysis:
Provided that the company is traded above 35.30, follow the recommendations below:
- Time frame: D1
- Recommendation: long position
- Entry point: 36.23
- Take Profit 1: 37.60
- Take Profit 2: 38.10
Alternative scenario:
In case of breakdown of the level 35.30, follow the recommendations below:
- Time frame: D1
- Recommendation: short position
- Entry point: 35.30
- Take Profit 1: 34.30
- Take Profit 2: 33.80
No comments:
Post a Comment